Compare Johnson Controls International PLC (JCI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Recursion Pharmaceuticals Inc — how do they compare? Johnson Controls International PLC trades at $155.35 (market cap $93.28B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: Johnson Controls International PLC is far larger — about 43.6× Recursion Pharmaceuticals Inc's market cap, and Johnson Controls International PLC pays a 1.04% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 65 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| JCI | RXRX | |
|---|---|---|
Market Cap | $93.28B | $2.14B |
Volume | 2,786,476 | 30,789,535 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $6.79 |
52-Week Low | $105.55 | $2.84 |
Typical Hold Time | 65 Days | 22 Days |
Enterprise Value | $102.12B | $1.66B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JCI trades at $155.93, down 1.78% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported robust Q3 2026 earnings, beating estimates with $1.42 EPS and raising full-year guidance, driven by 10% organic sales growth and a record $21 billion backlog. Profitability remains solid with a 14.32% net income margin and 24.42% ROE.
The stock offers upside to the $172.50 consensus price target, supported by strong fundamentals and institutional accumulation. Risks include elevated valuation multiples (P/E 43.38) and potential macroeconomic pressures on industrial demand. Continued execution on data center and building systems growth is key for sustained momentum.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
